Independent proxy advisory firm Institutional Shareholder Services recommended NuVasive shareholder to vote in favor of the devicemaker's proposed merger with Globus Medical, according to an April 14 news release.
The ISS' report said the merger "appears to have strategic merit" and is "expected to generate cost and revenue synergies, with positive net synergies expected within two years."
The proposed union between Globus Medical and NuVasive was first announced in February. The deal values NuVasive at $3.1 billion and would bring together the two devicemaker's flagship spine technologies.
A few days after the deal was announced, Globus Medical shares took a hit, and some analysts expressed concern.
NuVasive is planning a special meeting of shareholders on April 27.